Dr. Amesh Adalja provides an update on the recent science breakthroughs and developments with the Zika virus. He reviews some of the clinical basics, microbiology, pathophysiological insights, and the future trajectory of the outbreak.
Educational objectives:
Upon completion of this activity, participants should be able to:
- Discuss the Zika virus outbreak from both a clinical and epidemiological standpoint
- Review Zika symptoms and diagnosis
- List the associated complications or impact of Zika
Reading Resources:
- Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Sakuntabhai A, Cao-Lormeau VM, Malasit P, Rey FA, Mongkolsapaya J, Screaton GR. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016 Sep;17(9):1102-8. doi: 10.1038/ni.3515.
- Sarno M, Sacramento GA, Khouri R, do Rosário MS, Costa F, Archanjo G, Santos LA, Nery N Jr, Vasilakis N, Ko AI, de Almeida AR. Zika Virus Infection and Stillbirths: A Case of Hydrops Fetalis, Hydranencephaly and Fetal Demise. PLoS Negl Trop Dis. 2016 Feb 25;10(2):e0004517. doi: 10.1371/journal.pntd.0004517.
- Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, Yao B, Shin J, Zhang F, Lee EM, Christian KM, Didier RA, Jin P, Song H, Ming GL. Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. Cell Stem Cell. 2016 May 5;18(5):587-90. doi: 10.1016/j.stem.2016.02.016.
Disclosures:
Dr. Adalja has reported no relevant relationships with entities producing health care goods or services/ has financial interests with the following any entity or entities producing health care goods or services as indicated below:
- CE Spearkers’ Bureau: Merck, Roche
- Stockholder: Merck, Evolent, Siga, Biocryst
All presenters disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
Accreditation Statement:
The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.075) continuing education units (CEU) which are equivalent to .75 contact hour.
For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.edu and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.
ABIM MOC Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive your ABIM MOC Part 2 credit, you will need to complete the post-test with a pass rate of 100% and provide your date of birth and ABIM number, along with the other required fields. This information will be shared with the American Board of Internal Medicine using the Accreditation Council for Continuing Medical Education Program and Activity Reporting System.
Release Date: 4/12/2017 | Last Modified On: 4/12/2017 | Expires: 2/20/2020
